Stock ENTO ENTERO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Real-time Estimate Cboe BZX
Other stock markets
 01:21:35 2024-05-23 pm EDT 		5-day change 1st Jan Change
2.81 USD -4.49% Intraday chart for Entero Therapeutics, Inc. -7.44% -34.76%
May. 20 Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index CI
May. 16 First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
AQ
Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index
CI
First Wave BioPharma Changes Name to Entero Therapeutics
AQ
First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index
CI
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
AQ
First Wave BioPharma, Inc. announced a financing transaction
CI
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
AQ
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
AQ
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
AQ
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
AQ
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
AQ
Sector Update: Health Care Stocks Retreating Late Afternoon
MT
Sector Update: Health Care
MT
First Wave BioPharma Shares Fall After Acquiring ImmunogenX
MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data
MT
First Wave Biopharma, Inc. Announces Management Changes
CI
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
AQ
First Wave BioPharma, Inc. completed the acquisition of ImmunogenX, LLC for $57.9 million.
CI
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENTO Stock
  4. News Entero Therapeutics, Inc.